Observational Study of T-cell Repertoire in AML Patients Undergoing Stem Cell Transplant
This research study is looking at the immune system in people with acute myeloid leukemia (AML) who are having a stem cell transplant. Researchers want to understand how the immune system's T-cells change before and after the transplant. By studying these T-cells, they hope to learn if the immune system plays a role in high-risk AML. You might be able to join if you have AML and are scheduled for a stem cell transplant at the University of Southern California (USC). The study will look at how long it takes for graft versus host disease (a condition where the donor's immune cells attack your body) or relapse (when the cancer comes back) to occur, for up to four years. The current recruitment status is unclear.
- Study design
- This is an observational study planning to include 250 participants. It is not a drug trial, but rather focuses on understanding the immune system.
- What's involved
- You would have blood samples collected before, 100 days after, and one year after your stem cell transplant. If you are a donor, your blood would be collected at the time of transplant.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will follow participants for up to four years to track the time to diagnosis of acute graft versus host disease and relapse.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Houda Alachkar, PharmD, PhD · PRINCIPAL_INVESTIGATOR · University of Southern California
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to diagnosis of acute graft versus (vs.) host disease (aGVHD)Up to 4 years
Will be calculated as the time from stem cell infusion until the date of the diagnosis of aGVHD. If a patient dies prior to day 100 and does not have aGVHD, the patient will be censored at the time of death; all patients without aGVHD will be censored on day 100.
- Time to diagnosis of relapseUp to 4 years
Will be calculated as the time from stem cell infusion until the date of the of the diagnosis of relapse Patients who die of treatment toxicity or other cause, prior to relapse, will be censored at the time of death; all patients will be censored at 365 days following transplant.